Degenerative Suspensory Ligament Desmitis (DSLD) in Peruvian Paso Horses Is Characterized by Altered Expression of TGFβ Signaling Components in Adipose-Derived Stromal Fibroblasts

PLoS One. 2016 Nov 30;11(11):e0167069. doi: 10.1371/journal.pone.0167069. eCollection 2016.

Abstract

Equine degenerative suspensory ligament desmitis (DSLD) in Peruvian Paso horses typically presents at 7-15 years and is characterized by lameness, focal disorganization of collagen fibrils, and chondroid deposition in the body of the ligament. With the aim of developing a test for disease risk (that can be used to screen horses before breeding) we have quantified the expression of 76 TGFβ-signaling target genes in adipose-derived stromal fibroblasts (ADSCs) from six DSLD-affected and five unaffected Paso horses. Remarkably, 35 of the genes showed lower expression (p<0.05) in cells from DSLD-affected animals and this differential was largely eliminated by addition of exogenous TGFβ1. Moreover, TGFβ1-mediated effects on expression were prevented by the TGFβR1/2 inhibitor LY2109761, showing that the signaling was via a TGFβR1/2 complex. The genes affected by the pathology indicate that it is associated with a generalized metabolic disturbance, since some of those most markedly altered in DSLD cells (ATF3, MAPK14, ACVRL1 (ALK1), SMAD6, FOS, CREBBP, NFKBIA, and TGFBR2) represent master-regulators in a wide range of cellular metabolic responses.

MeSH terms

  • Adipose Tissue / pathology*
  • Animals
  • Chromatin / metabolism
  • Fibroblasts / drug effects
  • Fibroblasts / pathology*
  • Gene Expression Regulation* / drug effects
  • Horse Diseases / pathology*
  • Horses
  • Ligaments*
  • Male
  • Protein Serine-Threonine Kinases / antagonists & inhibitors
  • Pyrazoles / pharmacology
  • Pyrroles / pharmacology
  • Receptor, Transforming Growth Factor-beta Type I
  • Receptor, Transforming Growth Factor-beta Type II
  • Receptors, Transforming Growth Factor beta / antagonists & inhibitors
  • Signal Transduction / drug effects
  • Stromal Cells / pathology*
  • Transforming Growth Factor beta / metabolism*
  • Transforming Growth Factor beta1 / pharmacology

Substances

  • Chromatin
  • LY2109761
  • Pyrazoles
  • Pyrroles
  • Receptors, Transforming Growth Factor beta
  • Transforming Growth Factor beta
  • Transforming Growth Factor beta1
  • Protein Serine-Threonine Kinases
  • Receptor, Transforming Growth Factor-beta Type I
  • Receptor, Transforming Growth Factor-beta Type II

Grants and funding

This study received funding from the Rush Arthritis Institute and the Katz/Rubschlager Endowed Chair. Funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.